Mark Curtis
Mark is a Business Development Analyst at the Centre for Commercialization of Regenerative Medicine (CCRM), where he collaborates with the team to help evaluate the commercial potential of regenerative medicine and cell therapy technologies. He began his career at Princess Margaret Hospital studying cellular reprogramming of human skin cells. Following this project, he left the laboratory and took on a role with Bloom Burton & Co., a healthcare-focused investment dealer. While there he supported the advisory team in carrying out scientific diligence on early-stage biotechnology companies. Prior to joining CCRM he was a consultant to Stem Cell Therapeutics, a Toronto-based biotechnology company focused on developing therapeutics targeting cancer stem cells. Mark received a Master’s degree from the University of New South Wales in Sydney, where he studied the directed differentiation of embryonic stem cells, and a Bachelor’s degree in Biology, from Queen’s University. Follow Mark on Twitter @markallencurtis
Posts by: Mark
Update from the Clinic: February
. Welcome to your Update from the Clinic for the month of February. Northwest Biotherapeutics received approval from Health Canada to proceed with its ongoing Phase 3 clinical study in Glioblastoma multiforme at clinical sites in Quebec. Sangamo and bluebird bio both had news on the regulatory progress of their respective beta-thalassemia programs. Kite Pharma […]
Regenerative Medicine Deal Review: January
. Welcome to your deal review for the month of January. There was a mixed bag of news last month, which included financing activity, industry partnerships and research collaborations. The cell therapy tools industry was front and centre as NeoStem and Invetech struck up a deal to develop a closed, automated cell manufacturing unit for […]
Update from the clinic: January
. Welcome to your Update from the Clinic for the month of January. Pluristem and OncoMed reported preliminary efficacy data from early-stage trials, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted a number of Orphan Drug Designations for various cancer indications being developed by OncoMed, Stemline Therapeutics, and Kite […]
The dermal cup, home to the elusive dermal stem cell
> The scientific community has long sought to uncover the identity of a true dermal stem cell. While many unique cell populations have been described in the literature, some of which are predictive of a dermal stem cell, the exact location and behavior of this cell has largely eluded us. In a landmark paper published […]
Update from the Clinic: March
. Welcome to your Update from the Clinic for the month of March. Investors weren’t so keen on Neuralstem’s topline results in amyotropic lateral sclerosis (ALS). NeoStem’s follow-up data from its PreSERVE study in acute myocardial infarction (AMI) was somewhat lacklustre. Northwest Biotherapeutics continues to report positive data on its DCVax technology, breathing hope into […]